Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 302

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

Open access
Harrison, Christine J., Hills, Robert K., Moorman, Anthony V., Grimwade, David J., Hann, Ian, Webb, David K.H., Wheatley, Keith, de Graaf, Siebold S.N., van den Berg, Eva, Burnett, Alan K., Gibson, Brenda E.S.·2010·Journal of Clinical Oncology

Abstract

Purpose: Karyotype is an independent indicator of prognosis in acute myeloid leukemia (AML) that is widely applied to risk-adapted therapy. Because AML is rare in children, the true prognostic significance of individual chromosomal abnormalities in this age group remains unclear. Patients and Methods: This cytogenetic study of 729 childhood patients classified them into 22 subgroups and evaluated their incidence and risk. Results: Rearrangements of 11q23 were the most frequent abnormality found in approximately 16% of patients, with 50% of these in infants. The outcome for all patients with 11q23 abnormalities was intermediate; no difference was observed for those with t(9;11)(p21-22;q23). The core binding factor leukemias with the translocations t(8;21)(q22;q22) and inv(16)(p13q22) occurred at incidences of 14% and 7%, respectively, predominantly in older children, and their prognosis was favorable. An adverse outcome was observed in patients with monosomy 7, abnormalities of 5q, and t(6;9)(p23;q34). Abnormalities of 3q and complex karyotypes, in the absence of favorable-risk features, have been associated with an adverse outcome in adults, but the results were not significant in this childhood series. However, the presence of 12p abnormalities predicted a poor outcome. Conclusion: Because the spectrum of chromosomal changes and their risk association seem to differ between children and adults with AML, biologic differences are emerging, which will contribute to the redefinition of risk stratification for different age groups in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.24.8997

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 302

Metadata

Authors
Harrison, C. J., Hills, R. K., Moorman, A. V., Grimwade, D. J., Hann, I., Webb, D. K. H., Wheatley, K., de Graaf, S. S. N., van den Berg, E., Burnett, A. K., & Gibson, B. E. S.
Venue
Journal of Clinical Oncology
Published
2010-06-01
Volume
28
Issue
16
Pages
2674-2681
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2144341550
Cited by
302
References
36
FWCI
14.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. https://app.cochat.ai/papers/10.1200/jco.2009.24.8997
The paper
Harrison, C. J., Hills, R. K., Moorman, A. V., Grimwade, D. J., Hann, I., Webb, D. K. H., Wheatley, K., de Graaf, S. S. N., van den Berg, E., Burnett, A. K., & Gibson, B. E. S. (2010). Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.24.8997

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.